Skip to main content

An official website of the United States government

You have 2 new alerts

Award Notice: Advanced Development, Scale-up, and Procurement of Ebanga

General Information

  • Contract Opportunity Type: Special Notice (Original)
  • Original Published Date: Aug 03, 2023 04:23 pm EDT
  • Original Response Date:
  • Inactive Policy: Manual
  • Original Inactive Date: Aug 03, 2023
  • Initiative:
    • None

Classification

  • Original Set Aside:
  • Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
  • NAICS Code:
    • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
  • Place of Performance:
    USA

Description

Medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak are a crucial component to the United States Government's (USGs) outbreak response plan. Biomedical Advanced Research and Development Authority (BARDA) is seeking to augment the USG?s response capabilities with therapeutics targeting filovirus disease caused by Ebola virus (EBOV), Marburg virus (MARV), or Sudan virus (SUDV). There are currently two US Food and Drug Administration (FDA) approved therapeutics for treatment of Ebola Virus Disease (EVD): Inmazeb/EB3 and Ebanga/mAb114. There are no therapeutics approved for the treatment of patients infected with SUDV or MARV.

Project BioShield (PBS) funding for this contract will support all efforts required for final development to approval, post-marketing requirements and commitments, manufacturing scale-up, and procurement of Final Drug Product (FDP) to be held as vendor managed inventory (VMI) or delivered to the Strategic National Stockpile.

Contact Information

Contracting Office Address

  • O’NEILL HOUSE OFFICE BUILDING
  • WASHINGTON , DC 20515
  • USA

Primary Point of Contact

Secondary Point of Contact

History

  • Aug 15, 2023 11:55 pm EDTSpecial Notice (Original)